Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Capital Expenditures (2022 - 2024)

Historic Capital Expenditures for Zentalis Pharmaceuticals (ZNTL) over the last 3 years, with Q2 2024 value amounting to $181000.0.

  • Zentalis Pharmaceuticals' Capital Expenditures fell 4326.02% to $181000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was $181000.0, marking a year-over-year decrease of 7094.7%. This contributed to the annual value of $221000.0 for FY2024, which is 6209.26% down from last year.
  • As of Q2 2024, Zentalis Pharmaceuticals' Capital Expenditures stood at $181000.0, which was down 4326.02% from $40000.0 recorded in Q1 2024.
  • In the past 5 years, Zentalis Pharmaceuticals' Capital Expenditures ranged from a high of $1.7 million in Q3 2022 and a low of $40000.0 during Q1 2024
  • Moreover, its 3-year median value for Capital Expenditures was $181000.0 (2024), whereas its average is $372444.4.
  • Data for Zentalis Pharmaceuticals' Capital Expenditures shows a peak YoY increase of 1474.82% (in 2023) and a maximum YoY decrease of 9451.81% (in 2023) over the last 5 years.
  • Over the past 3 years, Zentalis Pharmaceuticals' Capital Expenditures (Quarter) stood at $160000.0 in 2022, then increased by 8.12% to $173000.0 in 2023, then grew by 4.62% to $181000.0 in 2024.
  • Its Capital Expenditures stands at $181000.0 for Q2 2024, versus $40000.0 for Q1 2024 and $173000.0 for Q4 2023.